Please login to the form below

Not currently logged in
Email:
Password:

selumetinib

This page shows the latest selumetinib news and features for those working in and with pharma, biotech and healthcare.

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Today the spotlight has been turned on the other molecule in the co-development and co-commercialisation partnership, selumetinib, a MEK 1/2 inhibitor with potential across a range of targeted ... uses. The partners have just announced that the FDA has

Latest news

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    But now hopes are high for two late-stage drugs: olaparib and selumetinib. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics